Quattro Folia is one of the two initial phase business partner companies which are included into the cooperation consortium between Helsinki, Jyväskylä and Shanghai Jiao Tong (SJTU) universities. The cooperation agreement signed in June promotes interaction among researchers, exchanges of researchers and training co-operation, as well as corporate co-operation in the implementation of the new healthcare solutions. The aim of the cooperation is to develop treatment and prevention methods for chronic diseases. As part of the development, the intent is to use Balansio’s clinical intelligence, regulated medical devices and the ability of supported self-care to prevent the complication of diabetes.
Shanghai Jiao Tong (SJTU) university is one of the most prestigious universities in China and under its jurisdiction, there are 13 hospitals and China's first national translational medical infrastructure centre.
Another business partner also from Finland is Nightingale Health. With the help of their mass screening blood analysis technology, chronic diseases like cardiovascular disease and diabetes can be detected early and the prevention can be monitored efficiently. The solution enables analysis of a large number of samples and it is used by the leading international universities and biobanks.
Collaborative universities represent nationally leading and internationally recognized operators in selected areas. The Finnish companies involved in the cooperation, for their part, have developed leading solutions for the research, prevention and treatment of chronic diseases. In China, there is a growing need for this kind of solutions as the chronic diseases are affecting hundreds of millions of citizens. Through the consortium, the co-operation platform is designed to connect with new projects and partners and to promote Finnish medical and health technology in China and also for the other markets.
“It is very important for Quattro Folia to be apart of the research work which with we have a common mission. The possibility of being part of this research initiative we will be able to promote modern care technology and clinical intelligence enabling the prevention of the diabetes-related complications. At the same time, we are able to develop Balansio service to be more suitable for the new markets, based on the results of the research. This is a really important opportunity to show Finnish healthcare technology and know-how, which most likely will also open new doors in the China healthcare markets.” – comments CEO of Quattro Folia, Harri Okkonen.
Read more about the cooperation:
BALANSIO – SERVICE FOR SUPPORTED REMOTE DIABETES CARE
Balansio is designed to help diabetics to reach better daily care balance, to lower HbA1c levels and lower diabetes-related complication risk. The service enables clinicians to provide care and support based on the patients timely. This way blood glucose variations (hypos and hypers) and causes which leads to them can be detected in time and changes can be made immediately. This way we can reduce the amount of the hypos and hypers and achieve better care balance. Lifestyle and treatment changes can be done one be one which is the best way to achieve needed results towards better care balance.
Balansio includes smartphone application for Android and iOS phones and browser-based software – Balansio Pro for clinicians. The application receives data automatically from most common blood glucose meters, FreeStyle Libre (Finnish market) and activity applications. Additionally, carbohydrates and meal sizes, insulin and other self-care data can be input in the application manually. All the saved data to the application is available also for clinicians in Balansio Pro. Balansio’s clinical artificial intelligence identify different problems form the user’s data and give to user and clinician different observations and possible reasons and solutions to the problem. To solve the resource problem Balansio reduces the need for physical appointments because all the needed issues can be handled remotely. For clinicians, Balansio Pro brings up the patients who need attention and their key care guidance needs and organising the patients based on their care need. The application is integrated with A1c estimator to follow up the care results, bolus calculator for rapid-acting insulin calculation, and basal titrator to find the right dosage of basal insulin better. Balansio is a CE marked medical device.
* IDF Atlas (8th edition, 2017)
** Diabeteslitto, www.diabetes.fi/diabetes/yleista_diabeteksesta/tilastotietoa, 28.6.2018
Photo by Paavo Niutanen
QUATTRO FOLIA OY
Finnish startup company Quattro Folia was founded in 2012. Company’s mission is to promote care of the long-term diseases by using modern technology. Quattro Folia develops regulated and demanding CE marked clinical devices Software as a Service (Balansio) for professionals and individuals. Quattro Folia has also founded a specialized diabetes clinic “Lääkärikeskus Neliapila”, which has played a significant role in Balansio development. Now, the company has about 30 employees.
For more information:
VP, Business Development and Marketing
(+358) 50 486 7516
© Koodiviidakko Oy - Y-tunnus 1939962-1